Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance
Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 46 hrs
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (14 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (15 hrs)
Vitamin D trial shows reduced long‑COVID risk but no severity benefit (17 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.